JP2022515670A5 - - Google Patents
Info
- Publication number
- JP2022515670A5 JP2022515670A5 JP2021538284A JP2021538284A JP2022515670A5 JP 2022515670 A5 JP2022515670 A5 JP 2022515670A5 JP 2021538284 A JP2021538284 A JP 2021538284A JP 2021538284 A JP2021538284 A JP 2021538284A JP 2022515670 A5 JP2022515670 A5 JP 2022515670A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- approximately
- leukemia
- stereoisomers
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862787034P | 2018-12-31 | 2018-12-31 | |
| US62/787,034 | 2018-12-31 | ||
| PCT/US2019/068924 WO2020142422A1 (en) | 2018-12-31 | 2019-12-30 | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515670A JP2022515670A (ja) | 2022-02-21 |
| JP2022515670A5 true JP2022515670A5 (https=) | 2023-02-22 |
Family
ID=71121614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538284A Pending JP2022515670A (ja) | 2018-12-31 | 2019-12-30 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの組成物及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200206212A1 (https=) |
| EP (1) | EP3906030A4 (https=) |
| JP (1) | JP2022515670A (https=) |
| KR (1) | KR20210110616A (https=) |
| CN (1) | CN113347974A (https=) |
| AU (1) | AU2019418587A1 (https=) |
| BR (1) | BR112021012578A2 (https=) |
| CA (1) | CA3125189A1 (https=) |
| EA (1) | EA202191833A1 (https=) |
| IL (1) | IL284509A (https=) |
| MX (1) | MX2021007800A (https=) |
| SG (1) | SG11202106598QA (https=) |
| WO (1) | WO2020142422A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108601777B (zh) | 2016-01-08 | 2021-08-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 |
| JP2022554346A (ja) | 2019-11-05 | 2022-12-28 | セルジーン コーポレーション | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法 |
| MX2022006133A (es) | 2019-12-06 | 2022-06-17 | Celgene Corp | Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida. |
| US20240294489A1 (en) * | 2020-08-03 | 2024-09-05 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| EP4572804A2 (en) * | 2022-08-17 | 2025-06-25 | The Regents of the University of California | Inhalable compositions of cdk9 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| CN108601777B (zh) * | 2016-01-08 | 2021-08-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 |
| US10245258B2 (en) * | 2016-06-06 | 2019-04-02 | Celgene Corporation | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2019
- 2019-12-30 CN CN201980090422.3A patent/CN113347974A/zh active Pending
- 2019-12-30 SG SG11202106598QA patent/SG11202106598QA/en unknown
- 2019-12-30 EP EP19907888.2A patent/EP3906030A4/en not_active Withdrawn
- 2019-12-30 EA EA202191833A patent/EA202191833A1/ru unknown
- 2019-12-30 JP JP2021538284A patent/JP2022515670A/ja active Pending
- 2019-12-30 BR BR112021012578-7A patent/BR112021012578A2/pt not_active Application Discontinuation
- 2019-12-30 AU AU2019418587A patent/AU2019418587A1/en not_active Abandoned
- 2019-12-30 MX MX2021007800A patent/MX2021007800A/es unknown
- 2019-12-30 KR KR1020217022620A patent/KR20210110616A/ko not_active Withdrawn
- 2019-12-30 US US16/730,591 patent/US20200206212A1/en not_active Abandoned
- 2019-12-30 WO PCT/US2019/068924 patent/WO2020142422A1/en not_active Ceased
- 2019-12-30 CA CA3125189A patent/CA3125189A1/en active Pending
-
2021
- 2021-06-30 IL IL284509A patent/IL284509A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515670A5 (https=) | ||
| US20230212201A1 (en) | Stat3 degraders and uses thereof | |
| JP2020526501A5 (https=) | ||
| KR20240167633A (ko) | 종양 치료용 약학 조성물 | |
| RU2708247C2 (ru) | Соединение для лечения рака | |
| KR20220148847A (ko) | 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물 | |
| JP2023504230A (ja) | Ｐｒｍｔ５阻害剤の組合せ医薬 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| KR102282794B1 (ko) | 인돌리논 화합물의 용도 | |
| WO2015154725A1 (zh) | 喹唑啉衍生物及其制备方法和在医药上的应用 | |
| JP2018512403A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| JPWO2021060453A5 (https=) | ||
| Zhong et al. | Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways | |
| CN119403808A (zh) | 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂 | |
| KR20200102948A (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
| CA3233554A1 (en) | Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor | |
| JP5344910B2 (ja) | 薬剤耐性癌の処置方法 | |
| TW201636350A (zh) | 作為激酶調節劑之三唑並嗒 | |
| WO2014177915A1 (en) | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives | |
| CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
| CN113490497A (zh) | 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物 | |
| CN116261455A (zh) | 一种药物组合物及其在治疗癌症中的用途 | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| KR20250166103A (ko) | 종양 치료용 약제학적 조성물 | |
| HK40107305A (zh) | Mcl-1抑制剂与抗癌剂的组合 |